Last updated: September 5, 2026
Tecentriq, Roche’s atezolizumab, remains a major oncology product but is in a mature phase of its commercial life. Global sales peaked above CHF 3 billion annually and have declined as treatment guidelines favor competing PD-1 products, Roche faces pressure in lung and urothelial cancers, and older indications lose share. The principal medium-term protection is the biologic exclusivity period ending in May 2028, while patent and regulatory protections may delay practical biosimilar competition beyond that date.
Tecentriq’s financial outlook depends on three factors: continued use in lung cancer, uptake of the subcutaneous formulation Tecentriq Hybreza, and the speed at which biosimilar atezolizumab products enter major markets.
How much revenue does Tecentriq generate for Roche?
Tecentriq generated approximately CHF 3.1 billion in 2023, down from roughly CHF 3.4 billion in 2022, according to Roche annual reporting. Roche reported further decline in 2024 as competition increased and several indications matured.[1][2]
| Fiscal year |
Approximate Tecentriq sales |
Direction |
| 2021 |
CHF 3.1-3.3 billion |
Stable to modest decline |
| 2022 |
CHF 3.4 billion |
High point in the recent period |
| 2023 |
CHF 3.1 billion |
Decline |
| 2024 |
Approximately CHF 2.6-2.8 billion |
Further decline |
Tecentriq is strategically important but no longer one of Roche’s fastest-growing medicines. Its sales represent approximately 5%-7% of Roche’s pharmaceutical revenue, depending on the reporting year and currency effects. The product remains material to Roche’s oncology franchise, but it has less financial concentration than drugs such as Ocrevus or newer immunology and neuroscience assets.
What is driving Tecentriq’s revenue decline?
The main commercial pressures are:
- Increasing use of pembrolizumab, nivolumab and durvalumab in overlapping cancer indications.
- Greater physician familiarity with PD-1 therapies, particularly Keytruda.
- Loss of first-mover advantage in several solid tumors.
- Treatment sequencing that places Tecentriq behind other checkpoint inhibitors.
- Increased price pressure outside the United States.
- Maturing metastatic indications with limited patient growth.
- Clinical and commercial disappointment in selected expansion programs.
Tecentriq has retained stronger positions where Roche has combined it with chemotherapy, targeted therapy or antibody-drug conjugates. Its use in early-stage and perioperative lung cancer also provides a longer-duration opportunity than treatment of late-stage disease.
What is Tecentriq and which indications are approved?
Tecentriq is an intravenously administered monoclonal antibody that blocks PD-L1, preventing interaction with PD-1 and B7.1 immune checkpoints. The active ingredient is atezolizumab.
The FDA approved Tecentriq in 2016 for urothelial carcinoma. The product subsequently received approvals in non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma and alveolar soft part sarcoma, among other settings.[3]
Key U.S. indications include:
| Disease area |
Commercial relevance |
| Non-small cell lung cancer |
Largest strategic indication and primary source of long-term value |
| Extensive-stage small cell lung cancer |
Important but faces direct competition from Imfinzi |
| Hepatocellular carcinoma |
Combination with bevacizumab created a meaningful franchise |
| Urothelial carcinoma |
Earlier commercial anchor, now subject to significant competition |
| Alveolar soft part sarcoma |
Small population with orphan-disease economics |
| Early-stage lung cancer |
Growth opportunity through adjuvant and perioperative treatment |
The U.S. indication set has changed over time. Roche withdrew or discontinued certain indications where benefit-risk, commercial demand or competitive conditions weakened. In 2022, Roche voluntarily withdrew the U.S. indication for Tecentriq in platinum-refractory metastatic urothelial carcinoma after the FDA’s accelerated-approval framework tightened and confirmatory evidence did not support continued use.[4]
When does Tecentriq lose exclusivity?
The key U.S. regulatory exclusivity date is May 18, 2028, which is 12 years after FDA approval of the original biologic license application.[3][5]
| Protection |
Relevant date or period |
Commercial effect |
| FDA approval |
May 18, 2016 |
Start of U.S. biologic exclusivity period |
| Reference-product exclusivity |
May 18, 2028 |
Earliest statutory period for biosimilar approval based on the reference product |
| Biosimilar application timing |
Four years after approval for submission |
Biosimilar applicants could submit applications before 2028, subject to statutory rules |
| Practical market entry |
Potentially 2028 onward |
Depends on patents, litigation, settlement terms and FDA approval |
| Pediatric exclusivity |
No broadly reported six-month extension identified for Tecentriq |
No clear extension should be assumed |
Biologic exclusivity is different from small-molecule exclusivity. Tecentriq is not protected through the conventional Hatch-Waxman generic pathway. A competitor must pursue the biosimilar pathway under the Biologics Price Competition and Innovation Act.
The first biosimilar could reach the market around or after 2028 if an applicant completes development, receives FDA approval and resolves Roche’s patent rights. Actual entry could occur later if patent litigation produces an injunction, damages risk or a negotiated launch date.
What patents protect Tecentriq?
Tecentriq is protected by a layered biologic patent estate rather than a single product patent. Relevant categories include:
- Anti-PD-L1 antibody composition patents.
- Antibody sequence and binding patents.
- Cell-line and production patents.
- Formulation patents.
- Combination-treatment patents.
- Method-of-use patents covering specific tumor types and treatment regimens.
- Subcutaneous delivery and recombinant hyaluronidase technology for Tecentriq Hybreza.
Because biologics are not listed in the FDA Orange Book in the same way as small-molecule drugs, Tecentriq’s principal patent information is assessed through the FDA Purple Book, Roche patent publications, USPTO records and BPCIA litigation filings.[5]
What is the patent expiration timeline?
Roche’s core anti-PD-L1 patent families are expected to provide protection extending into the late 2020s and, for some claims, into the early 2030s. The relevant expiration date depends on the individual patent, patent-term adjustment, terminal disclaimer, claim scope and jurisdiction.
The commercial risk does not necessarily begin on the last expiration date. A biosimilar applicant may challenge patents before expiration, and Roche may assert multiple patent families covering different aspects of the product. Conversely, later-expiring formulation or manufacturing patents may have limited ability to block a biosimilar that uses a non-infringing process or formulation.
The most valuable remaining protection is likely to be:
- Core antibody claims that cover the active molecule.
- Manufacturing claims that are difficult to design around.
- Subcutaneous formulation and delivery claims for Tecentriq Hybreza.
- Newer method-of-use claims in early-stage lung cancer.
What is the Orange Book status of Tecentriq?
Tecentriq is a biologic and does not rely on a standard Orange Book patent-listing strategy. The appropriate FDA reference source is the Purple Book, which identifies licensed biologics and biosimilars.[5]
Tecentriq’s exclusivity analysis therefore requires review of:
- The original biologics license application.
- FDA Purple Book reference-product status.
- Published Roche and Genentech patent families.
- Any BPCIA patent-exchange activity.
- Federal court filings involving atezolizumab.
- Patent-term adjustment and terminal-disclaimer records.
The absence of a conventional Orange Book listing does not mean the product lacks patent protection. It means the legal pathway for challenging and listing relevant rights is different.
How strong is the Tecentriq patent estate?
Tecentriq has a moderate-to-strong patent estate through the end of the decade, but its long-term blocking power depends on the enforceability of composition claims and the breadth of manufacturing patents.
Strengths
- PD-L1 antibody composition claims can directly cover the biosimilar molecule.
- Biologic manufacturing processes are complex and difficult to replicate without extensive development.
- Roche has multiple opportunities to assert method-of-use and formulation patents.
- Tecentriq Hybreza creates a newer layer of delivery-related protection.
- The product has a large commercial base, which supports litigation spending.
Weaknesses
- A biosimilar may challenge individual patents selectively.
- Some method-of-use claims may not block use in every approved indication.
- Later-expiring patents may not prevent launch if a competitor uses a different formulation or manufacturing process.
- PD-L1 and PD-1 products have substantial clinical interchangeability from a payer perspective.
- The commercial value of later patent protection could decline before legal expiry because of therapeutic substitution.
The patent estate is more defensible for the molecule and complex manufacturing process than for broad treatment-method claims in crowded checkpoint-inhibitor indications.
Are biosimilars likely to challenge Tecentriq?
Yes. Tecentriq is a likely biosimilar target because it has:
- Multi-billion-dollar annual sales.
- A well-established mechanism.
- Large patient populations in lung cancer.
- A biologic exclusivity date in 2028.
- Manufacturing processes that are technically challenging but commercially attractive.
- A market with demonstrated acceptance of oncology biosimilars.
No U.S. atezolizumab biosimilar had achieved broad commercial penetration as of the latest publicly available period. The main competitive threat remains future biosimilar entry rather than an established current biosimilar franchise.
What generic or biosimilar launch scenarios exist?
| Scenario |
Likely commercial outcome |
| First biosimilar launches near 2028 |
Rapid price discount and hospital-account pressure |
| Launch delayed by patent settlement |
Roche retains substantial U.S. revenue through the settlement date |
| Multiple biosimilars launch together |
Faster price erosion and lower switching barriers |
| Only one biosimilar launches initially |
Moderate discount, with Roche retaining premium positioning |
| Tecentriq Hybreza gains adoption |
Some erosion shifts from IV Tecentriq to protected or differentiated SC use |
| Biosimilar enters IV market but not SC market |
Roche preserves part of administration-related value |
The likely first impact will be on hospital and institutional accounts. Payers may prefer biosimilar substitution where interchangeability, contracting and supply reliability support it. Roche can mitigate erosion through contracting, combination regimens, formulation differentiation and lifecycle management.
What is the commercial impact of Tecentriq Hybreza?
In September 2024, the FDA approved Tecentriq Hybreza, a subcutaneous formulation of atezolizumab combined with recombinant human hyaluronidase, for eligible adult patients across specified Tecentriq indications.[6]
The product uses Roche’s partnership with Halozyme’s ENHANZE drug-delivery technology. Tecentriq Hybreza can reduce administration time compared with intravenous infusion, which may lower chair-time costs and improve treatment-center throughput.
The commercial effect will depend on:
- Reimbursement parity with intravenous Tecentriq.
- Hospital adoption.
- Patient preference.
- Availability across approved indications.
- Payer treatment policies.
- Roche’s ability to secure formulation and delivery patents.
- Whether biosimilar competitors develop only IV products or also pursue subcutaneous versions.
Tecentriq Hybreza is a lifecycle-management tool rather than a complete defense against biosimilar erosion. It can preserve revenue in settings where convenience and infusion-center capacity matter, but its value is limited if payers treat the formulations as interchangeable and apply aggressive discounts.
How does Tecentriq compare with Keytruda, Opdivo and Imfinzi?
| Product |
Active ingredient |
Company |
Primary competitive position |
| Tecentriq |
Atezolizumab |
Roche/Genentech |
PD-L1 inhibitor with lung, liver and selected rare-tumor positions |
| Keytruda |
Pembrolizumab |
Merck |
Broadest oncology footprint and dominant commercial scale |
| Opdivo |
Nivolumab |
Bristol Myers Squibb |
Broad PD-1 franchise with major combination use |
| Imfinzi |
Durvalumab |
AstraZeneca |
Strong lung-cancer and hepatobiliary positioning |
| Libtayo |
Cemiplimab |
Regeneron/Sanofi |
More focused PD-1 portfolio |
Keytruda has the strongest overall competitive position because of its number of indications, early-stage use and commercial scale. Imfinzi is a particularly important competitor in lung cancer, including limited-stage and extensive-stage small cell lung cancer. Opdivo is strongest in combination regimens and selected gastrointestinal and thoracic cancers.
Tecentriq’s relative advantage is its combination with Avastin in hepatocellular carcinoma and its integration into Roche’s oncology portfolio. Its disadvantage is weaker overall market share and lower differentiation in settings where PD-1 and PD-L1 mechanisms are viewed as therapeutically interchangeable.
What litigation affects Tecentriq?
The principal future litigation risk is expected to involve BPCIA patent disputes brought by Roche against atezolizumab biosimilar developers. Those disputes may address:
- Antibody composition claims.
- Biosimilar manufacturing processes.
- Formulation claims.
- Subcutaneous delivery technology.
- Treatment-method claims.
- Patent-term and obviousness challenges.
As of the latest publicly available period, no major U.S. biosimilar settlement had established a publicly recognized atezolizumab launch date. The absence of a disclosed settlement means the 2028 regulatory exclusivity date remains the clearest baseline for U.S. competitive timing.
Any settlement could permit an earlier authorized launch, a delayed entry date, or a license with supply and royalty terms. Roche’s negotiating leverage will be highest before the first biosimilar approval and decline as more competitors approach market entry.
What licensing deals support Tecentriq’s lifecycle strategy?
Roche’s most relevant product-related licensing relationship is with Halozyme for ENHANZE technology used in subcutaneous drug delivery. The technology supports Tecentriq Hybreza and other Roche lifecycle-management programs.[7]
The commercial purpose is clear:
- Extend differentiation beyond the IV product.
- Reduce treatment-center administration time.
- Improve convenience.
- Protect a portion of revenue after IV biosimilar entry.
- Create additional patent claims around formulation and delivery.
The deal does not eliminate biosimilar risk because a competitor may develop a separate subcutaneous formulation or compete through the established IV route.
What is the FDA regulatory status of Tecentriq?
Tecentriq is FDA approved, with multiple indications and a subcutaneous formulation approved as Tecentriq Hybreza. Its regulatory profile is mature, but indication-level risk remains relevant because accelerated approvals may require confirmatory evidence and can be withdrawn.
The FDA has increased scrutiny of oncology indications supported by surrogate endpoints, especially where postmarketing trials fail to confirm clinical benefit. This creates a continuing risk for narrower or older Tecentriq indications even though the core product remains firmly established.
What is the outlook for Tecentriq revenue?
The base-case trajectory is continued decline before 2028, followed by sharper erosion once an atezolizumab biosimilar enters the U.S. market.
| Period |
Expected market dynamic |
| 2025-2027 |
Gradual decline from competition and mature indications |
| 2028 |
First major biosimilar risk point in the United States |
| 2029-2030 |
Greater contracting pressure and possible multi-biosimilar competition |
| After 2030 |
Residual value from early-stage use, rare tumors, combinations and SC delivery |
Tecentriq’s revenue floor will depend on the mix of indications rather than total patient volume alone. Early-stage treatment produces longer-duration use and may be less vulnerable to rapid switching than short-course metastatic therapy. Rare-tumor approvals can retain high per-patient value but cannot offset broad-market erosion.
Key Takeaways
- Tecentriq sales peaked at approximately CHF 3.4 billion in 2022 and declined thereafter.
- Roche faces its largest competitive exposure in lung cancer, where Keytruda and Imfinzi have strong positions.
- U.S. biologic exclusivity runs through May 18, 2028.
- Tecentriq is assessed through the Purple Book and BPCIA framework, not a conventional Orange Book listing.
- Roche’s patent estate includes composition, manufacturing, formulation and method-of-use rights.
- Tecentriq Hybreza provides lifecycle protection and administration convenience but will not fully prevent biosimilar erosion.
- The most likely financial path is gradual pre-2028 decline followed by faster erosion after U.S. biosimilar entry.
- Roche’s strongest defenses are early-stage lung-cancer use, combination regimens, manufacturing complexity and subcutaneous delivery.
FAQs About Tecentriq Market Dynamics and Exclusivity
Is Tecentriq still a blockbuster drug?
Yes. Tecentriq remains a multibillion-franc product, although sales have declined from their recent peak and the drug is in a mature commercial phase.
Will Tecentriq lose exclusivity in 2028?
The primary U.S. biologic exclusivity period ends in May 2028. Patent litigation, settlements and additional patent rights may delay practical biosimilar entry.
Is Tecentriq listed in the Orange Book?
No conventional Orange Book analysis applies because Tecentriq is a biologic. The FDA Purple Book and BPCIA patent process are the relevant frameworks.
Does Tecentriq Hybreza extend Roche’s patent protection?
Tecentriq Hybreza creates additional formulation and delivery-related protection, but the strength and duration of that protection depend on individual patents and claim scope.
Which Roche product competes most directly with Tecentriq?
Within the checkpoint-inhibitor market, Imfinzi is a particularly direct competitor in lung cancer. Keytruda is the broader commercial benchmark because of its larger indication base and market share.
Sources
- Roche Holding AG. (2024). Annual report 2023.
- Roche Holding AG. (2025). Annual report 2024.
- U.S. Food and Drug Administration. (2016). FDA approves atezolizumab for bladder cancer.
- U.S. Food and Drug Administration. (2022). Withdrawal of approval of atezolizumab indication for metastatic urothelial carcinoma.
- U.S. Food and Drug Administration. (2025). Purple Book: Database of licensed biological products.
- U.S. Food and Drug Administration. (2024). Tecentriq Hybreza prescribing information.
- Halozyme Therapeutics, Inc. (2021). Roche collaboration for ENHANZE drug-delivery technology.
